EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, JFL Life Sciences's Enterprise Value is ₹472.0 Mil.
JFL Life Sciences's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2025 was ₹-39.3 Mil. Therefore, JFL Life Sciences's EV-to-FCF for today is -12.02.
The historical rank and industry rank for JFL Life Sciences's EV-to-FCF or its related term are showing as below:
NSE:JFLLIFE'
s EV-to-FCF Range Over the Past 10 Years
Min: -20.84 Med: -5.44 Max: 135.19
Current: -12.02
During the past 7 years, the highest EV-to-FCF of JFL Life Sciences was 135.19. The lowest was -20.84. And the median was -5.44.
NSE:JFLLIFE's EV-to-FCF is ranked worse than 100% of 562
companies
in the Drug Manufacturers industry
Industry Median: 20.955
vs NSE:JFLLIFE: -12.02
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
JFL Life Sciences (NSE:JFLLIFE) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
JFL Life Sciences's PE Ratio (TTM) for today is calculated as:
JFL Life Sciences's share price for today is ₹10.60.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. JFL Life Sciences's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2025 was ₹1.203.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
JFL Life Sciences EV-to-FCF Related Terms
JFL Life Sciences EV-to-FCF Historical Data
* Premium members only.
The historical data trend for JFL Life Sciences's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, JFL Life Sciences's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
JFL Life Sciences EV-to-FCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, JFL Life Sciences's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where JFL Life Sciences's EV-to-FCF falls into.
JFL Life Sciences's current Enterprise Value is ₹472.0 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. JFL Life Sciences's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2025 was ₹-39.3 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
JFL Life Sciences (NSE:JFLLIFE) has a EV-to-FCF of -12.02 as of Jul. 12, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on JFL Life Sciences and its competitors. According to the industry distribution chart, JFL Life Sciences ranks #999999 out of 562 companies in the Drug Manufacturers industry.
Is JFL Life Sciences' EV-to-FCF too high?
JFL Life Sciences' current EV-to-FCF is -12.02. Based on the distribution chart, JFL Life Sciences ranks #999999 out of 562 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, JFL Life Sciences has a GF Score™ of 72/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does JFL Life Sciences' EV-to-FCF compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, JFL Life Sciences ranks #999999 out of 562 companies for EV-to-FCF. This places JFL Life Sciences in the lower half of its industry. The industry median EV-to-FCF is 20.96. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Drug Manufacturers company?
The median EV-to-FCF among Drug Manufacturers companies is 20.96, based on 562 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on JFL Life Sciences and its competitors. For the Drug Manufacturers industry, the median EV-to-FCF is 20.96 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. JFL Life Sciences's current EV-to-FCF is -12.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is JFL Life Sciences stock overvalued right now?
Based on GuruFocus' analysis, JFL Life Sciences (NSE:JFLLIFE) is currently considered Significantly Undervalued. The stock's GF Value™ is ₹35.85, compared to a current price of ₹10.60 — trading 70.4% below its estimated fair value. The current EV-to-FCF is -12.02. JFL Life Sciences' overall GF Score™ is 72/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For JFL Life Sciences (NSE:JFLLIFE), the current EV-to-FCF is -12.02 as of Jul. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is JFL Life Sciences (NSE:JFLLIFE) Overvalued in 2026?
Based on GuruFocus' analysis, JFL Life Sciences stock appears to be undervalued.
The current stock price of ₹10.60 is trading 70.4% below its estimated GF Value™ of ₹35.85.
GuruFocus considers JFL Life Sciences to be Significantly Undervalued.
Key valuation signals for NSE:JFLLIFE:
EV-to-FCF: -12.02
GF Value™: ₹35.85 vs. price of ₹10.60 (70.4% below fair value)
No single metric tells the full story. See the NSE:JFLLIFE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
JFL Life Sciences Ltd is engaged in the business of manufacturing pharmaceutical products. The company's product portfolio consists of Dry powder injections (B-Lactam), Tablets and Capsules (B-Lactam) solid oral dosage forms, and general tablets and capsules. Its operating segment comprises of manufacturing and selling of pharmaceutical products. Geographically, the company sells its products both in India and outside India.
72GF Score
Get the complete analysis for NSE:JFLLIFE
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:JFLLIFE has been successfully added to your 